Mercedes K. Meyer, Ph.D. opines on and oversees global patent portfolio management, development, strategy, investment and acquisition. She has experience with due diligence, patent interferences, reexamination, drug pricing, patent prosecution ethics and bioethics issues. Mercedes helps clients protect innovations in such areas as antibodies, enzymes, viral vectors, genomics, nucleic acids, vaccines, stem cell research, gene therapy, drug screening and identification, food and beverages, animal health products, and industrial enzymes for biofuels and cosmetics.
With a doctorate in virology from the University of Texas M.D. Anderson Cancer Center and a bachelor’s degree in chemistry, Mercedes has an intimate understanding of complex biotechnology and chemical subjects. She collaborates with her life sciences clients from start-ups to Fortune 500 companies on their patent portfolio strategy and manages an extensive biotechnology and pharmaceutical patent prosecution practice, especially in corporate joint development projects. She also works with the boards of directors of start-ups for innovation monetization.
A strategic thinker, Mercedes is familiar with issues relating to 35 U.S.C. §101 and subject-matter eligibility and 35 U.S.C. §203 Bayh-Dole march-in issues. She also experted in suits involving potential ethics violations arising from patent prosecution.
Mercedes is an active member of the American Intellectual Property Law Association (AIPLA), where she was a former board member and secretary, and of the Intellectual Property Owner’s Organization (IPO), IPO Education Foundation (IPOEF), and the Association of University Technology Managers Women’s Inventor Committee. She is co-author of Patent Ethics: Prosecution (2016−2017, 4th edition) with David Hricik. Mercedes is selected for inclusion on Managing Intellectual Property (IP) Stars, the IAM 300 Leading IP Strategists, and the IAM Patent 1000 World’s Leading Patent Practitioners lists.
- Provides frequent joint party representation to protect collaborative works between multiple corporations and universities.
- Has obtained patent term extension on several patents under 35 USC 156.
- Successfully cancelled claims in third party reexamination.
- Regularly performs due diligence and white space analysis in fields such as antibodies, medical devices, and vaccines.
- Frequent speaker on ethics issues such as professionalism, mental health, legal advertising, and conflicts of interest.
- Regularly speaks on patent eligibility issues, gender parity in innovation and entrepreneurship and women lawyers.
Fellow, American Intellectual Property Law Association (2013–Present)
"Top Strategist," IAM Strategy 300: the World's Leading IP Strategists (2017–Present)
IAM Patent 1000, Intellectual Asset Management (2012–Present)
MIP Stars Top 250 Women in IP, Managing Intellectual Property (2013–Present)
Awards Methodology (www.drinkerbiddle.com/content/awards)
Vice Chair of the IPO Women in IP Committee (2016 IPO Outstanding Committee of the Year Award Winner),
Co-Chair of the Diversity Committee of FCBA
Patent Ethics: Prosecution
- District of Columbia
- U.S. Patent and Trademark Office
- University of Houston, J.D., 1996
- University of Texas, Ph.D., Virology, 1994
- Bryn Mawr College, B.A., Chemistry, 1988
- Intellectual Property Owners Organization, Vice Chair Women’s Committee (2016–2020)
- Intellectual Property Owners Education Foundation, Board Member (May 2019–December 2020)
- American Intellectual Property Law Association (AIPLA), Board of Directors (2009–2011)
- AIPLA, Secretary (2011–2012)
- Federal Circuit Bar Association, Co-Chair, Diversity (2015–2018)
- AIPLA, Biotechnology Committee, (Past Vice Chair 2007–2009)
- AIPLA, Women in IP Law Committee, (Past Chair 2005–2007)